Turmeric is used every single day by hundreds of millions of people across South Asia, across the Middle East, across Africa, in every curry made anywhere in the world. It has been used as food and medicine for over four thousand years.
It is on a European restriction list.
I want to explain to you why, and I want to explain to you why the regulatory concern — which is real — is being applied to the wrong product, with consequences that will affect everyone who wants access to turmeric-based supplements.
The concern — stated fairly.
Health Canada has reviewed over sixty international case reports of liver injury in people using turmeric or curcumin-containing products. Sixty is not a small number. Some of those cases were serious. The Australian Therapeutic Goods Administration has issued a safety alert. The EU's HoA Working Group placed curcumin on its priority list for restriction. There is a documented adverse event signal.
The formulation distinction — the most important fact in this debate.
Here is what every single one of those reports has in common, and what none of the regulators are leading with in their public communications.
Not one of those 60-plus hepatotoxicity case reports involves food-grade turmeric. Not one. Every case, without exception, involved an engineered, high-bioavailability curcumin extract. Products specifically formulated to get around the fact that ordinary curcumin is very poorly absorbed — less than 1% of it makes it into the bloodstream from a standard preparation.
The supplement industry created products designed to dramatically increase that absorption. They used piperine — extracted from black pepper — which increases curcumin bioavailability by approximately 20 times. They used nanoparticle delivery systems. Phospholipid complexes. Lecithin emulsification. These are not food products. They are pharmaceutical-grade delivery technologies applied to a food component.
And when you increase the blood concentration of curcumin 20-fold, you get a pharmacological entity that is fundamentally different from the turmeric your grandmother put in dhal. The hepatotoxicity signal is not from turmeric. It is from what the supplement industry did to curcumin in order to sell it as a more potent product.
The scientific literature is unambiguous on this point. The peer-reviewed Italian Phytovigilance database analysis states it clearly: in all cases, hepatotoxicity was associated with Curcuma longa formulations with high bioavailability and high dosage of curcumin. A 2026 review in Tandfonline confirms the same: no safety concern has been identified for turmeric when used as a spice or consumed in foods as part of a typical diet.
The JECFA safety evaluation.
The Joint FAO/WHO Expert Committee on Food Additives evaluated curcumin safety at its 52nd meeting in 2004. They established an acceptable daily intake of 3 milligrams per kilogram of body weight per day — approximately 210 milligrams per day for a 70-kilogram adult — based on a no-observed-adverse-effect level from reproductive toxicity studies. EFSA agreed with this evaluation in 2010.
Now note what that means: the international food safety evaluation set an ADI for curcumin as a food additive, at a dose consistent with dietary exposure — not as a ceiling for therapeutic use. Phase I clinical trials published by Lao and colleagues in BMC Complementary and Alternative Medicine found no maximum tolerated dose was established at single doses up to 12,000 milligrams of standard curcumin extract. No hepatotoxicity. No dose-limiting toxicity.
The safety concern is specific to formulations that circumvent the natural absorption limit.
The proportionality argument.
Let me give you the pharmaceutical comparator. Ibuprofen and other non-steroidal anti-inflammatory drugs — NSAIDs — cause between 12,000 and 15,000 hospital admissions for gastrointestinal bleeding every year in the United Kingdom. They are available over the counter in supermarkets. Paracetamol accounts for approximately 56% of severe acute liver injury in UK specialist liver units and generates roughly 47,500 A&E attendances annually. Neither is under restriction.
Sixty case reports — all involving specialised formulations, none involving food — is the basis for restricting a root vegetable that feeds a billion people safely every day.
What proportionate regulation looks like.
The appropriate regulatory response is quality standards that distinguish between food-grade turmeric preparations and high-bioavailability curcumin extracts. Standard turmeric tincture, standard powder, standard whole-herb preparations — no hepatotoxicity concern; no regulatory intervention required. High-bioavailability curcumin formulations with piperine or nanoparticle delivery — require labelling of bioavailability method, dose guidance, and practitioner caution for patients with liver conditions. That is proportionate. Blanket restriction on curcumin catches the food and the medicine together
This is food. Four thousand years of food. A food that is currently being treated as a pharmaceutical hazard because of what commercial supplement manufacturers did to an isolated extract of one of its constituents.
The UK Government has committed to align food supplement law with EU food supplement law under the SPS Agreement — without a parliamentary vote. The legislation in scope is published at www.gov.uk/government/news/uk-eu-sps-agreement-legislation-in-scope .
https://www.change.org/p/demand-uk-regain-control-over-food-supplements-regulation?recruiter=1403120945&recruited_by_id=ca366360-0a66-11f1-a119-071922cd5010&utm_source=share_petition&utm_campaign=petition_dashboard&utm_medium=copylink&share_id=Qv72WrhZDN
Write to your MP at writetothem.com. Sign the petition. Respond to the EU consultation. And ask whether Parliament will vote before these restrictions become British law.
#RightToHeal #HerbalAccessNI #SaveOurSupplements
